-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

628.O1.6 628. Aggressive Lymphomas: Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas

Symposia: Aggressive Lymphomas: Cellular Therapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Translational Research, Lymphomas, Non-Hodgkin lymphoma, Drug development, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Real-world evidence, Aggressive lymphoma, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Study Population, Human
Saturday, December 7, 2024: 9:30 AM-11:00 AM
Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)
Moderators:
Elise A. Chong, MD, ARRAY(0xea8847c) and Andrew P Jallouk, MD, PhD, Vanderbilt University Medical Center
Disclosures:
Jallouk: Kite/Gilead: Consultancy, Research Funding; Allogene Therapeutics: Research Funding.
9:30 AM

Peter A. Riedell, MD1*, Mi Kwon, MD, PhD2, Ian W. Flinn, MD, PhD3, Michael J. Dickinson, MBBS, DMedSci4, Carlos Solano, MD, PhD5, Ulrich Jaeger, MD6, Javier Briones7*, Koji Kato, MD, PhD8, Shaun Fleming, MBBS, FRACP, FRACPA9*, Emmanuel Bachy, MD, PhD10, Alessandro Rambaldi11, Leyla O. Shune, MD12, Nirav N. Shah, MD13, Didier Blaise, MD14*, Matthew J. Frigault, MD15*, Aravind Ramakrishnan, MD16, Anne Yang, PhD17*, David Pearson, PhD18*, Aiesha Zia, MSc19*, Eduardo Segura, MD20*, Aisha Masood, MD17 and Pere Barba, MD21

1David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL
2Department of Hematology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
3Tennessee Oncology/OneOncology, Nashville, TN
4Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, VIC, Australia
5Department of Hematology, Hospital Clínico Universitario, University of Valencia, Valencia, Spain
6Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Vienna General Hospital – Medical University of Vienna, Vienna, Austria
7Hematology and Hemotherapy Department, Hospital de la Sant Creu i Sant Pau. IIB-Sant Pau and José Carreras Leukemia Research Institutes. Universitat Autónoma de Barcelona, Barcelona, Spain
8Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka Prefecture, Japan
9Department of Haematology, Alfred Hospital, Melbourne, VIC, Australia
10Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Lyon, France
11Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
12University of Kansas Medical Center, Kansas City, KS
13Medical College of Wisconsin, Milwaukee, WI
14Département d’Hématologie, Programme de Transplantation et de Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille University, Institut Paoli Calmettes, Marseille, France
15Massachusetts General Hospital, Boston, MA
16Department of Hematology, St David's South Austin Medical Center, Austin, TX
17Novartis Pharmaceuticals Corporation, East Hanover, NJ
18Novartis Institutes for BioMedical Research, Basel, Switzerland
19Novartis Pharma AG, Basel, Switzerland
20Novartis Pharmaceuticals Corporation, Madrid, Spain
21Hematology Department, Hospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain

9:45 AM

Nirav N. Shah, MD1, Richard T. Maziarz, MD2, Caron A. Jacobson, MD, MMSc3, Patrick B. Johnston, MD, PhD4*, Sunil Abhyankar, MD5, Iris Isufi, MD6, Miguel Angel Perales, MD7, Monalisa Ghosh, MD8, Matthew Ulrickson, MD9, Allison C. Rosenthal, DO10, Javier L. Munoz, MD, MS, MBA11, Nancy M. Hardy, MD12, Aaron P. Rapoport, MD12, Reem Karmali, MD13, Farrukh T. Awan, MD14, Matthew Stuart McKinney, MD15, Mitchell Horwitz, MD15, Matthew Lunning, DO16, Nathan Denlinger, DO, MS17, Marek Ancukiewicz, PhD18*, Madhavi Nallewar, MD18*, Kimberly C Coleman, RN18*, Esther Eromosele, MD18*, Remigiusz Kaleta, MD18*, Johanna Theruvath, MD18*, Anna Wijatyk, MD18* and David B. Miklos, MD, PhD19

1Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI
2Knight Cancer Institute, Oregon Health and Science University, Portland, OR
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Mayo Clinic, Rochester, MN
5Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
6Division of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
7Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
8Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
9Banner/MD Anderson Cancer Center, Gilbert, AZ
10Division of Hematology/Oncology Mayo Clinic, Phoenix, AZ
11Mayo Clinic Arizona, Phoenix, AZ
12University of Maryland School of Medicine, Baltimore, MD
13Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
14Division of Hematology and Oncology, The Ohio State University, Dallas, TX
15Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
16Heme/Onc, University of Nebraska, Omaha, NE
17Division of Hematology, The Ohio State University, Columbus, OH
18Miltenyi Biomedicine, Gaithersburg, MD
19Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA

10:00 AM

Anne Marijn Kramer, MD, PhD1,2, John H. Baird, MD3, Hrishikesh Srinagesh, MD, MSCR4*, Emily Egeler5*, Kendall Levine6*, Annie K. Brown, MS7*, Sharon Mavroukakis, MS5*, Kristen Cunanan, PhD8*, Yi-Jiun Su, MD4,9*, Neha Agarwal, MS2,4*, Mark P. Hamilton, MD, PhD10,11,12, Sushma Bharadwaj, MD13, Sally Arai, MD14, Laura Johnston, MD14, Robert Lowsky, MD14*, Everett H. Meyer, MD, PhD15, Robert S. Negrin, MD14, Andrew R. Rezvani14*, Judith Shizuru14*, Lekha Mikkilineni, MD, MA11, Hitomi Hosoya, MD, PhD11, Parveen Shiraz14*, Surbhi Sidana, MD16, Wen-Kai Weng, MD, PhD11, Vanessa E. Kennedy, MD11, Melody Smith, MD, MS16, Saurabh Dahiya, MD11, Kara L. Davis, DO17*, Sneha Ramakrishna, MD18*, Liora Michal Schultz, MD18, Ramya Tunuguntla, PhD19*, Steven A. Feldman, PhD2*, Lori Muffly, MD16, Crystal L. Mackall, MD5, David B. Miklos, MD, PhD10,11 and Matthew J. Frank14,20

1Cancer Center Amsterdam, Department of Hematology, Amsterdam UMC, Amsterdam, Netherlands
2Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA
3Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
4Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
5Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
6Department of Bone Marrow Transplant and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
7Laboratory of Cell and Gene Medicine, Stanford University School of Medicine, Palo Alto, CA
8Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, CA
9Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan
10Stanford Cancer Institute, Center for Cancer Cell Therapy, Stanford University, Stanford, CA
11Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
12Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
13Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA
14Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
15Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University Medical Center, Stanford, CA
16Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
17Stanford University, Stanford, CA
18Department of Pediatrics, Division of Hematology and Oncology, Stanford University School of Medicine, Palo Alto, CA
19Center for Cancer Cell Therapy, Stanford University, Stanford, CA
20Stanford Cancer Institute, Center for Cancer Cell Therapy, Stanford University School of Medicine, Stanford, CA

10:15 AM

Armin Ghobadi, MD1, Robert Baiocchi, MD, PhD2, Amer M. Beitinjaneh, MD, MS3*, Sridhar Chaganti, MD, PhD, FRCPath, MRCP4*, Sylvain Choquet, MD5*, Daan Dierickx6, Rajani Dinavahi, MD7, Xinyuan Duan8*, Laurence Gamelin8*, Kris Michael Mahadeo, MD9, Aditi Mehta, DO10, Sarah Nikiforow, MD, PhD11, Ran Reshef, MD, MSc12, Sandrine Roye13*, Jean-Claude Vedovato, MD14* and Susan E Prockop, MD15*

1Division of Oncology, Washington University School of Medicine, St. Louis, MO
2James Comprehensive Cancer Center, The Ohio State University, Columbus, OH
3Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL
4Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
5Hopital Pitié-Salpetriere, AP-HP, Paris, FRA
6University Hospitals Leuven, Leuven, Belgium
7AtaraBio, Thousand Oaks, CA
8ATARABio, Thousand Oaks, CA
9Pediatric Transplant and Cellular Therapy, Duke University, Durham, NC
10Atara Biotherapeutics, South San Francisco, CA
11Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
12Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
13Institut de Recherche Pierre Fabre, Pierre Fabre Laboratories, Toulouse, France
14Pierre Fabre Laboratories, Boulogne Billancourt, FRA
15Stem Cell Transplant Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA

10:30 AM

Alaa Ali, MD1, Nausheen Ahmed, MD2, Soyoung Kim, PhD3,4*, Matthew Bye, MPH3*, Sayeef Mirza, MD, MPH5, Alex Gordon Sieg, MD, MS6, Christopher Strouse, MD7, Kalyan Nadiminti, MBBS8, Priyanka A. Pophali, MD8, Rammurti T. Kamble, MD9*, Lohith Gowda, MD10*, Cameron J. Turtle, MBBS, PhD11,12,13*, Christine L. Phillips, MD14, Marcelo C. Pasquini, MD, MS3, Sairah Ahmed, MD15, Siddhartha Ganguly, MD16 and Amy Moskop, MD3,17

1Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
2Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
3CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
4Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI
5Hematology, Yale School of Medicine, New Haven
6University of Iowa, Iowa City, IA
7Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
8Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI
9Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital, Houston, TX
10Yale Cancer Center and Yale School of Medicine, New Haven, CT
11Department of Medicine, University of Washington, Seattle, WA
12Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
13University of Sydney, Sydney, NSW, Australia
14Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
15Department of Lymphoma/Myeloma and Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX
16Houston Methodist Hospital and Neal Cancer Center, Houston, TX
17Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI

10:45 AM

Lara Stepan, BS1*, Sahar Ansari, PhD1*, Abood Okal, PhD2*, Justine Dell’Aringa, BS1*, Ethan G. Thompson, PhD1*, Alessandro Crotta, MD3*, Victor A. Chow, MD1*, Jeremy S. Abramson, MD4, Manali Kamdar, MD, MBBS5*, Scott R. Solomon, MD6, Patrick B. Johnston, MD, PhD7*, Bertram Glass, MD8*, Pim Mutsaers, MD9*, Jon E. Arnason, MD10, Stephan Mielke, MD11, Mazyar Shadman, MD, MPH12*, Francisco Hernandez-Ilizaliturri, MD13, Koji Izutsu, MD, PhD14, Veronika Bachanova, MD, PhD15, Sami Ibrahimi, MD16, Jacob Chabon, PhD17*, David Kurtz, MD, PhD18, Ash A. Alizadeh, MD, PhD19 and Leanne Peiser, DPhil1*

1Bristol Myers Squibb, Seattle, WA
2Bristol Myers Squibb, Cambridge, MA
3Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland
4Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
5University of Colorado Cancer Center, Aurora, CO
6Northside Hospital Cancer Institute, Atlanta, GA
7Mayo Clinic, Rochester, MN
8Department of Hematology and Stem Cell Transplantation, Helios Klinikum Berlin-Buch, Berlin, Germany
9Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
10Beth Israel Deaconess Medical Center, Boston, MA
11Karolinska Institutet and University Hospital; Karolinska Comprehensive Cancer Center, Karolinska ATMP Center, Stockholm, Sweden
12Fred Hutch Cancer Center, University of Washington, Seattle, WA
13Department of Medicine (Lymphoma Section), Roswell Park Comprehensive Cancer Center, Buffalo, NY
14National Cancer Center Hospital, Tokyo, Japan
15University of Minnesota, Minneapolis, MN
16University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK
17Foresight Diagnostics, Aurora, CO
18Department of Medicine (Oncology), Stanford University, Palo Alto, CA
19Stanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine, Stanford, CA

*signifies non-member of ASH